Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Rapt Therapeutics, Inc.

Clinical trials sponsored by Rapt Therapeutics, Inc., explained in plain language.

RAPT Therapeutics, Inc. RAPT NASDAQ

Develops oral small-molecule therapies for inflammatory diseases and cancer.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 1 Terminated 2

New shot could let food allergy sufferers eat peanuts and milk safely

Disease control Recruiting now

This study tests a new drug called RPT904 in about 100 people aged 12 to 55 who are allergic to foods like peanut, milk, egg, cashew, or walnut. RPT904 is a long-acting antibody that blocks allergic reactions and may only need to be given every 8 to 12 weeks. The goal is to see i…

Phase: PHASE2 • Sponsor: RAPT Therapeutics, Inc. • Aim: Disease control

Last updated Jul 30, 2026 00:00 UTC